item management s discussion and analysis of financial condition and results of operations 
years ended december  and operating loss for the year ended december  decreased  or from the year ended december  the decrease in the operating loss was principally due to purchased research and development charged to expense in resulting from various purchases of technology in that year predominantly the nexell purchase in december resulting in a  charge to expense 
there was no purchased research and development charged to expense in this was offset by increased operating loss principally due to the first full year of operations of nexell 
during that year  sales increased  or  cost of goods sold increased  or resulting in an increase in the gross profit of  operating expenses decreased due to the decrease in purchased research and development discussed above offset by research and development expenses which increased  or  general and administrative increased  or  selling expense was effectively recorded for the first time in at  and one time restructuring costs amounting to  were recorded 
the increase in revenues and the related cost of goods sold resulted from the inclusion of a full year of sales in compared to sales recorded after the nexell acquisition in december reflecting the initial purchase of inventory by nexell s sole distributor  baxter 
the gross profit percentage was in as compared to in this difference resulted principally from adjustments made in to record the nexell acquisition on the purchase method 
the company recorded a write off of purchased in process technology of million in principally related to the acquisition of the immunotherapy division of the biotech business group of baxter healthcare corporation 
this amount represented an allocation of purchase price to projects that primarily were aimed at the approval of the nexell s isolex products in the united states and certain foreign countries 
such amount was charged to expense because the projects related to research and development that had not reached technological feasibility and for which there was no alternative future use 
the research and development expense increase of  or resulted from an increase due to the inclusion of a full year of activity for nexell  offset by decreases in spending in vgi  vimrx  and innovir 
general and administrative expenses and amortization of goodwill increased by  or is due principally to the inclusion of nexell  offset by decreases in expenses in vimrx and innovir 
selling and marketing expenses were incurred by nexell as it ramped up marketing efforts in europe and prepared for approval of its products by the fda in the united states 
restructuring costs include expenses related to the shutdown of innovir s facilities see footnote 
interest income increased  or due to an increase in the average funds available for investment 
interest expense increased  principally due to the interest in the long term debt due to a related party 
minority interest in net loss of a consolidated subsidiary increased  or due principally to the inclusion of nexell in  offset by a decrease in the participation of the minority interest in the losses of innovir 
the foregoing resulted in a  or decrease in the net loss for the year ended december  years ended december  and total operating expenses increased by  or due principally to a  or increase in purchased research and development 
the  purchased research and development charge recorded in was principally due to the acquisition of the immunotherapy division of the biotech business group of baxter healthcare corporation nexell 
in addition  research and development increased  or and general and administration expense increased  or 
the increase in research and development expense from  in to  in was principally due  to costs incurred by vgi in its collaboration with columbia  expenses incurred at innovir  which was purchased in december   therefore  the first full year of expenses was  and increased spending on vimrx s research programs the increase in general and administrative expense from  in to  in was due principally to a full year of costs related to innovir which increased  over the  incurred in minority interest in net loss of consolidated subsidiary increased  due to the losses incurred by innovir and vgi 
revenue and cost of goods sold resulting in a gross profit of  in are a result of the operations of nexell which acquired the assets and operations of baxter s immunotherapy division in december the foregoing resulted in an increase in the net loss of  liquidity and capital resources before fiscal the company had not realized any operating revenues and has financed its operations through the sale of its securities 
the company had  in cash and cash equivalents as of december  as compared to  in cash and cash equivalents as of december  and working capital of  at december  as compared to  at december  most of the decrease in cash and working capital positions resulted from the cash used in the operations of the company of approximately  cash used in operating activities increased approximately  or over the cash used in operating activities in the year ended december  due principally to the inclusion of nexell and the step up of nexell operations offset by the curtailment of operations in innovir  vgi and vimrx development programs 
the company expects to incur substantial expenditures in the foreseeable future for the research and development and commercialization of its proposed products 
based on current projections  which are subject to change  the company s management believes that the present balance of cash and cash equivalents is sufficient to fund its operations for over one and one half years  assuming no capital infusions are received 
thereafter  the company will require additional funds  which it may seek to raise through public or private equity or debt financings  collaborative or other arrangements with corporate sources  or through other sources of financing 
year issues the company is aware of and has addressed many of the year issues associated with both information technology it and non it systems which could cause problems and network failures should the systems fail to recognize year designations after the company has reviewed its own computer  communication  software and operating systems and is satisfied they are year compliant 
furthermore  the company has taken proactive measures to ensure the systems are year compliant by upgrading all server and workstation operating systems 
all system servers and workstations bios have been reprogrammed and are year compliant the bios are responsible for starting the computer by providing a basic set of instructions 
it performs all the tasks which need to be done at start up time 
the company has upgraded all productivity  communication and accounting software to meet year compliance 
the company has tested the accounting systems with the year date and feels confident they are compliant 
the company will plan system wide testing in the first and second quarters of any system failures will be addressed at that time 
the company feels its year risks are minimal 
the company has spent approximately  to upgrade its systems which brought the company into year readiness 
the company will continue to contact critical suppliers  collaborators  partners and vendors to determine if their operations  as they relate to the company  are year compliant 
although the company will take all practical measures to prevent problems related with the year programming issue  such problems and failures may occur which could seriously affect the company s progress 
because of the unprecedented nature of such problems  the extent of the effect on the company s progress cannot be certain 
new accounting pronouncements in march  the accounting standards executive committee issued statement of position  accounting for the costs of computer software developed or obtained for internal use statement 
once the capitalization criteria of statement have been met  external directs costs of materials and services consumed in developing or obtaining internal use computer software  payroll and payroll related costs for employees who are directly associated with and who devote time to the internal use computer software project to the extent of the time spent directly on the project  and interest costs incurred when developing computer software for internal use should be capitalized 
training costs and data conversion costs  should be expensed as incurred 
statement is effective for financial statements for fiscal years beginning after december   with earlier application encouraged 
the adoption of this standard is not expected to have a material impact on the company s earning or financial position 
in april  the accounting standards executive committee issued statement of position  reporting on the costs of start up activities the statement 
the statement requires costs of start up activities  including organizational costs  to be expensed as incurred 
start up activities are defined as those one time activities related to opening a new facility  introducing a new product or service  conducting businesses in a new territory  conducting business with a new process in an existing facility  or commencing a new operation 
the statement is effective for fiscal years beginning after december  the adoption of this standard is not expected to have a material impact on the company s earning or financial position 
in june  the fasb issued statement of financial accounting standards no  accounting for derivative instruments and hedging activities statement 
statement establishes accounting and reporting standards for derivative instruments  including certain derivative instruments embedded in other contracts  and for hedging activities 
statement requires that an entity recognize all derivatives as either assets or liabilities in the statement of financial position and measure the instrument at fair value 
the accounting changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation 
this statement is effective for all fiscal quarters beginning after june  the company intends to adopt this accounting standard as required 
the adoption of this standard is not expected to have a material impact on the company s earnings or financial position 
item a 
quantitative and qualitative disclosures about market risk the company maintains excess cash in a mutual fund  the blackrock low duration bond portfolio  the fund which invests in asset backed securities  bonds and various other commercial obligations 
the fund may  from time to time  use certain derivatives in its investment strategy 
two of the main risk disclosed by the fund are interest rate risk and credit risk 
typically  when interest rates rise  there is a corresponding decline in the market value of bonds such as those held by the fund 
credit risk refers the possibility that the issues of the bond will not be able to make principal and interest payments 

